{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Renal+Insufficiency+Chronic&page=3",
    "query": {
      "condition": "Renal Insufficiency Chronic",
      "page": 3
    },
    "page_size": 10
  },
  "pagination": {
    "page": 3,
    "page_size": 10,
    "total_count": 1654,
    "total_pages": 166,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Renal+Insufficiency+Chronic&page=4&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Renal+Insufficiency+Chronic&page=2&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-05T21:39:43.508Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05908084",
      "title": "To Compare the Efficacy and Safety of the ATEV With AVF in Female Patients With End-Stage Renal Disease Requiring Hemodialysis",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "End Stage Renal Disease (ESRD)"
      ],
      "interventions": [
        {
          "name": "Acellular Tissue Engineered Vessel (ATEV)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "AVF",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Humacyte, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 121,
      "start_date": "2023-09-07",
      "completion_date": "2028-06",
      "has_results": false,
      "last_update_posted_date": "2026-06-26",
      "last_synced_at": "2026-10-05T21:39:43.508Z",
      "location_count": 32,
      "location_summary": "Scottsdale, Arizona • El Centro, California • La Jolla, California + 25 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "El Centro",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05908084"
    },
    {
      "nct_id": "NCT01970176",
      "title": "Study to Determine How Cialis Effects the Renal Function in Response to Volume Expansion in Preclinical Systolic Cardiomyopathy (Aim2)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Cardiomyopathy",
        "Renal Impairment"
      ],
      "interventions": [
        {
          "name": "Tadalafil",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "21 Years to 90 Years"
      },
      "enrollment_count": 20,
      "start_date": "2014-01-09",
      "completion_date": "2019-09",
      "has_results": true,
      "last_update_posted_date": "2021-06-11",
      "last_synced_at": "2026-10-05T21:39:43.508Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01970176"
    },
    {
      "nct_id": "NCT06516653",
      "title": "Post Market Study for VasQ, an External Support Implant for Arteriovenous Fistula",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "End Stage Renal Disease"
      ],
      "interventions": [
        {
          "name": "VasQ",
          "type": "DEVICE"
        },
        {
          "name": "Arteriovenous fistula creation for dialysis vascular access",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "PROCEDURE"
      ],
      "sponsor": "Laminate Medical Technologies",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 300,
      "start_date": "2025-01-13",
      "completion_date": "2028-05",
      "has_results": false,
      "last_update_posted_date": "2026-07-14",
      "last_synced_at": "2026-10-05T21:39:43.508Z",
      "location_count": 9,
      "location_summary": "Long Beach, California • Sarasota, Florida • Atlanta, Georgia + 6 more",
      "locations": [
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Sarasota",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Greenwood",
          "state": "Mississippi"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06516653"
    },
    {
      "nct_id": "NCT04053764",
      "title": "Study Exploring the Effect of Crizanlizumab on Kidney Function in Patients With Chronic Kidney Disease Caused by Sickle Cell Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Sickle Cell Disease (SCD)"
      ],
      "interventions": [
        {
          "name": "Crizanlizuamb",
          "type": "DRUG"
        },
        {
          "name": "Standard of Care",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 58,
      "start_date": "2019-12-10",
      "completion_date": "2023-03-20",
      "has_results": true,
      "last_update_posted_date": "2024-10-09",
      "last_synced_at": "2026-10-05T21:39:43.508Z",
      "location_count": 6,
      "location_summary": "Birmingham, Alabama • Chicago, Illinois • Baton Rouge, Louisiana + 3 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Baton Rouge",
          "state": "Louisiana"
        },
        {
          "city": "Greenville",
          "state": "North Carolina"
        },
        {
          "city": "Memphis",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04053764"
    },
    {
      "nct_id": "NCT00441545",
      "title": "Head to Head Study Against Sevelamer Hydrochloride",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Chronic Kidney Disease, Stage 5"
      ],
      "interventions": [
        {
          "name": "Fosrenol (Lanthanum Carbonate)",
          "type": "DRUG"
        },
        {
          "name": "Sevelamer hydrochloride",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Shire",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 182,
      "start_date": "2007-01-05",
      "completion_date": "2008-07-31",
      "has_results": true,
      "last_update_posted_date": "2021-06-11",
      "last_synced_at": "2026-10-05T21:39:43.508Z",
      "location_count": 34,
      "location_summary": "Mesa, Arizona • Phoenix, Arizona • Tempe, Arizona + 29 more",
      "locations": [
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tempe",
          "state": "Arizona"
        },
        {
          "city": "Tempe",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00441545"
    },
    {
      "nct_id": "NCT00890045",
      "title": "Hemodialysis Reliable Outflow (HeRO) Vascular Access Patency Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Renal Failure Chronic Requiring Hemodialysis"
      ],
      "interventions": [
        {
          "name": "HeRO Vascular Access Device",
          "type": "DEVICE"
        },
        {
          "name": "Conventional ePTFE hemodialysis graft",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Merit Medical Systems, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "22 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "22 Years to 99 Years"
      },
      "enrollment_count": 72,
      "start_date": "2004-07",
      "completion_date": "2008-03",
      "has_results": true,
      "last_update_posted_date": "2024-01-29",
      "last_synced_at": "2026-10-05T21:39:43.508Z",
      "location_count": 11,
      "location_summary": "Los Angeles, California • Miami, Florida • Atlanta, Georgia + 8 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Springfield",
          "state": "Illinois"
        },
        {
          "city": "Rockville",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00890045"
    },
    {
      "nct_id": "NCT03457701",
      "title": "Anemia Studies in CKD: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat- Iron (ASCEND: Fe)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Anaemia"
      ],
      "interventions": [
        {
          "name": "Daprodustat",
          "type": "DRUG"
        },
        {
          "name": "rhEPO",
          "type": "DRUG"
        },
        {
          "name": "Ferrous sulfate containing the stable iron isotope (57Fe)",
          "type": "DRUG"
        },
        {
          "name": "Ferrous sulfate containing the stable iron isotope (58Fe)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 15,
      "start_date": "2019-07-30",
      "completion_date": "2022-07-05",
      "has_results": true,
      "last_update_posted_date": "2024-03-27",
      "last_synced_at": "2026-10-05T21:39:43.508Z",
      "location_count": 3,
      "location_summary": "Fort Worth, Texas • Lufkin, Texas • San Antonio, Texas",
      "locations": [
        {
          "city": "Fort Worth",
          "state": "Texas"
        },
        {
          "city": "Lufkin",
          "state": "Texas"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03457701"
    },
    {
      "nct_id": "NCT05932901",
      "title": "OPTIMISE-CKD Drug Utilization",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Chronic Kidney Disease"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "130 Years",
        "sex": "ALL",
        "summary": "18 Years to 130 Years"
      },
      "enrollment_count": 2682052,
      "start_date": "2022-05-04",
      "completion_date": "2023-09-28",
      "has_results": false,
      "last_update_posted_date": "2024-04-17",
      "last_synced_at": "2026-10-05T21:39:43.508Z",
      "location_count": 1,
      "location_summary": "Minneota, Minnesota",
      "locations": [
        {
          "city": "Minneota",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05932901"
    },
    {
      "nct_id": "NCT05803421",
      "title": "A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Type 2 Diabetes",
        "Obesity",
        "Overweight or Obesity",
        "Overweight",
        "Cardiovascular Diseases",
        "Chronic Kidney Disease"
      ],
      "interventions": [
        {
          "name": "Orforglipron",
          "type": "DRUG"
        },
        {
          "name": "Insulin Glargine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2749,
      "start_date": "2023-04-03",
      "completion_date": "2026-03-16",
      "has_results": false,
      "last_update_posted_date": "2026-04-17",
      "last_synced_at": "2026-10-05T21:39:43.508Z",
      "location_count": 173,
      "location_summary": "Daphne, Alabama • Mobile, Alabama • Pelham, Alabama + 149 more",
      "locations": [
        {
          "city": "Daphne",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Pelham",
          "state": "Alabama"
        },
        {
          "city": "Sheffield",
          "state": "Alabama"
        },
        {
          "city": "Chandler",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05803421"
    },
    {
      "nct_id": "NCT03055299",
      "title": "COMEX Study for Dialysis Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "ESRD"
      ],
      "interventions": [
        {
          "name": "COMEX intervention",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "University of Pittsburgh",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 40,
      "start_date": "2017-02-20",
      "completion_date": "2018-04-30",
      "has_results": false,
      "last_update_posted_date": "2018-07-03",
      "last_synced_at": "2026-10-05T21:39:43.508Z",
      "location_count": 1,
      "location_summary": "Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03055299"
    }
  ]
}